3Tauber M, Chevrel J, Diene G, et al. Long-term evolution of endo- crine disorders and effect of GH therapy in 35 patients with pituitary stalk interruption syndrome [ J ]. Horm Res,2005,64 ( 6 ) :266-273.
4eqijayanand P, Mahadevan S, So Shivbalan, et al. Pituitary stalk in- terruption syndrome [ J ]. Indian Journal of Pediatrics, 2007,74 (9) : 874-875.
5Arrigo T, Wasniewska M, De Luca F, et al. Congenital adenohy- pophysis aplasia: Clinical features and analysis of the transcriptional factors for embryonic pituitary development[ J]. J Endocrinol Invest, 2006,29 ( 3 ) :208-213.
6Turton JP, Mehta A, Raza J, et al. Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD) [ J]. Clin Endocrino, 2005, 63(1) :10-18.
7Rottembourg D, Linglart A, Adamsbaum C, et al. Gonadotrophic status in adolescents with pituitary stalk interruption syndrome [ J]. Clin Endocrinol 2008,69 : 105-111.
8El Chehadeh S, Bensignor C, de Monlon JV, et al. The pituitary stalk interruption syndrome: endocrine features and benefits of growth hormone therapy [ J ]. Ann Endocrino1,2010,71 : 102-110.
9Pinto G, Netchine I, Sobrier ML, et al. Pituitary stalk interruption syndrome : a clinical-biological-genetic assessment of its pathogenesis [J]. Clin Endocrinol Metab, 1997,82:3450-3454.
10Bozzola M, Mengarda F, Sartirana P, et al. Long-term follow-up e- valuation of magnetic resonance imaging in the prognosis of perma- nent GH deficiency [ J ]. Eur J Endocrinol,2000,143 (4) :493-496.
